{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:25:12Z","timestamp":1785839112119,"version":"3.56.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1378\/chest.12-2396","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T06:04:02Z","timestamp":1380607442000},"page":"1346-1356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"title":["Systemic Sclerosis-Associated Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"144","author":[{"given":"Neal F.","family":"Chaisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1378\/chest.12-2396_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-140-1-200401060-00010","article-title":"Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis","volume":"140","author":"Jimenez","year":"2004","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1378\/chest.12-2396_bib2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1378\/chest.12-2396_bib3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982-2006","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1378\/chest.12-2396_bib4","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1378\/chest.12-2396_bib5","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.22069","article-title":"Clinical differences between idiopathic and scleroderma-related pulmonary hypertension","volume":"54","author":"Fisher","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1378\/chest.12-2396_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/annrheumdis-2011-200265","article-title":"The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH","volume":"71","author":"Clements","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"suppl 1","key":"10.1378\/chest.12-2396_bib7","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","article-title":"Updated clinical classification of pulmonary hypertension","volume":"54","author":"Simonneau","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1378\/chest.12-2396_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0889-857X(03)00022-X","article-title":"Scleroderma epidemiology","volume":"29","author":"Mayes","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"issue":"5","key":"10.1378\/chest.12-2396_bib9","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/rheumatology\/keh124","article-title":"A study of the prevalence of systemic sclerosis in northeast England","volume":"43","author":"Allcock","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1378\/chest.12-2396_bib10","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"issue":"9129","key":"10.1378\/chest.12-2396_bib11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(98)02111-4","article-title":"Primary pulmonary hypertension","volume":"352","author":"Gaine","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1378\/chest.12-2396_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1378\/chest.12-2396_bib13","first-page":"269","article-title":"Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma","volume":"33","author":"Chang","year":"2006","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1378\/chest.12-2396_bib14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1445-5994.2004.00646.x","article-title":"Isolated pulmonary hypertension in scleroderma","volume":"35","author":"Cox","year":"2005","journal-title":"Intern Med J"},{"issue":"2","key":"10.1378\/chest.12-2396_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1378\/chest.12-2396_bib16","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3899\/jrheum.101243","article-title":"Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population","volume":"38","author":"Hinchcliff","year":"2011","journal-title":"J Rheumatol"},{"issue":"16","key":"10.1378\/chest.12-2396_bib17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1378\/chest.12-2396_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s12016-011-8265-z","article-title":"The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension","volume":"44","author":"Kherbeck","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"issue":"19","key":"10.1378\/chest.12-2396_bib19","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.12-2396_bib20","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1183\/09031936.05.00045705","article-title":"Autoimmunity and pulmonary hypertension: a perspective","volume":"26","author":"Nicolls","year":"2005","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1378\/chest.12-2396_bib21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1378\/chest.12-2396_bib22","first-page":"462","article-title":"Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1378\/chest.12-2396_bib23","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1172\/JCI2261","article-title":"The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis","volume":"101","author":"Bordron","year":"1998","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1378\/chest.12-2396_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1378\/chest.12-2396_bib25","first-page":"583","article-title":"IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts","volume":"2","author":"Tamby","year":"2008","journal-title":"Biologics"},{"issue":"1","key":"10.1378\/chest.12-2396_bib26","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"issue":"11","key":"10.1378\/chest.12-2396_bib27","first-page":"2379","article-title":"Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations","volume":"29","author":"Morse","year":"2002","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1378\/chest.12-2396_bib28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ccm.2006.11.007","article-title":"Genetics and mediators in pulmonary arterial hypertension","volume":"28","author":"Austin","year":"2007","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.1378\/chest.12-2396_bib29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/rheumatology\/kel378","article-title":"Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension","volume":"46","author":"Wipff","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1378\/chest.12-2396_bib30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0025-6196(11)61030-6","article-title":"Pulmonary hypertension in patients with interstitial lung diseases","volume":"82","author":"Ryu","year":"2007","journal-title":"Mayo Clinic Proc"},{"issue":"4","key":"10.1378\/chest.12-2396_bib31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/rheumatology\/40.4.453","article-title":"Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival","volume":"40","author":"MacGregor","year":"2001","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1378\/chest.12-2396_bib32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1378\/chest.12-2396_bib33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","article-title":"Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease","volume":"60","author":"Mathai","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1378\/chest.12-2396_bib34","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/art.30423","article-title":"Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies","volume":"63","author":"Le Pavec","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1378\/chest.12-2396_bib35","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/BOR.0b013e32833dfbd8","article-title":"Cardiac complications of systemic sclerosis: recent progress in diagnosis","volume":"22","author":"Boueiz","year":"2010","journal-title":"Curr Opin Rheumatol"},{"issue":"12","key":"10.1378\/chest.12-2396_bib36","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/37.12.1320","article-title":"A study of the frequency of pericardial and pleural effusions in scleroderma","volume":"37","author":"Thompson","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"1","key":"10.1378\/chest.12-2396_bib37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/ard.2006.057760","article-title":"Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis","volume":"67","author":"de Groote","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1378\/chest.12-2396_bib38","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.healun.2004.12.113","article-title":"Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases","volume":"24","author":"Girgis","year":"2005","journal-title":"J Hearth Lung Transplant"},{"issue":"2","key":"10.1378\/chest.12-2396_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.berh.2008.01.008","article-title":"Musculoskeletal involvement in systemic sclerosis","volume":"22","author":"Randone","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"16","key":"10.1378\/chest.12-2396_bib40","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/CIRCULATIONAHA.109.192230","volume":"119","author":"McLaughlin","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1378\/chest.12-2396_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/ers.11.18","article-title":"Pulmonary arterial hypertension associated with systemic sclerosis","volume":"5","author":"Mathai","year":"2011","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"10.1378\/chest.12-2396_bib42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.200912-1820OC","article-title":"Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension","volume":"182","author":"Campo","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1378\/chest.12-2396_bib43","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1002\/art.24525","article-title":"The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France","volume":"60","author":"Hachulla","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1378\/chest.12-2396_bib44","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/rheumatology\/ken488","article-title":"Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French Itin\u00e9rAIR-Scl\u00e9rodermie study","volume":"48","author":"Hachulla","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1378\/chest.12-2396_bib45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/hrt.2010.212084","article-title":"Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis","volume":"97","author":"Janda","year":"2011","journal-title":"Heart"},{"issue":"6","key":"10.1378\/chest.12-2396_bib46","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1183\/09031936.00139009","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"34","author":"Gaili\u00e8","year":"2009","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1378\/chest.12-2396_bib47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/rheumatology\/keh067","article-title":"Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis","volume":"43","author":"Mukerjee","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1378\/chest.12-2396_bib48","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3899\/jrheum.090997","article-title":"Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis","volume":"37","author":"Cavagna","year":"2010","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1378\/chest.12-2396_bib49","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/BOR.0b013e32834ba6a7","article-title":"Pulmonary hypertension: screening and evaluation in scleroderma","volume":"23","author":"York","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1378\/chest.12-2396_bib50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis","volume":"58","author":"Allanore","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1378\/chest.12-2396_bib51","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.30535","article-title":"Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests","volume":"63","author":"Schreiber","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1378\/chest.12-2396_bib52","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1002\/art.30432","article-title":"Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations","volume":"63","author":"Meune","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"4_MeetingAbstracts","key":"10.1378\/chest.12-2396_bib53","doi-asserted-by":"crossref","first-page":"809A","DOI":"10.1378\/chest.1387106","article-title":"An evidence-based screening algorithm for pulmonary arterial hypertension in systemic sclerosis: the DETECT study [abstract]","volume":"142","author":"McLaughlin","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1378\/chest.12-2396_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2010.08.004","article-title":"Pulmonary hypertension in systemic sclerosis","volume":"41","author":"Chatterjee","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"17","key":"10.1378\/chest.12-2396_bib55","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/0002-9149(91)90330-N","article-title":"Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease","volume":"68","author":"Alpert","year":"1991","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1378\/chest.12-2396_bib56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension. A national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1378\/chest.12-2396_bib57","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/000331979604700505","article-title":"Noninvasive evaluation of right ventricle systolic pressure during dynamic exercise by saline-enhanced Doppler echocardiography in progressive systemic sclerosis","volume":"47","author":"Mininni","year":"1996","journal-title":"Angiology"},{"issue":"1","key":"10.1378\/chest.12-2396_bib58","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1378\/chest.130.1.176","article-title":"Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma","volume":"130","author":"Alkotob","year":"2006","journal-title":"Chest"},{"issue":"1","key":"10.1378\/chest.12-2396_bib59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.07-2324","article-title":"Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis","volume":"134","author":"Steen","year":"2008","journal-title":"Chest"},{"issue":"4","key":"10.1378\/chest.12-2396_bib60","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/art.33460","article-title":"Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure","volume":"64","author":"Kovacs","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1378\/chest.12-2396_bib61","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1183\/09031936.00145608","article-title":"Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review","volume":"34","author":"Kovacs","year":"2009","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1378\/chest.12-2396_bib62","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.12-2396_bib63","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"issue":"20","key":"10.1378\/chest.12-2396_bib64","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1378\/chest.12-2396_bib65","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1378\/chest.12-2396_bib66","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1378\/chest.12-2396_bib67","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Gali\u00e9","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1378\/chest.12-2396_bib68","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/ard.2007.077149","article-title":"Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials","volume":"67","author":"Avouac","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1378\/chest.12-2396_bib69","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.rmed.2011.12.018","article-title":"Dual therapy in IPAH and SSc-PAH. A qualitative systematic review","volume":"106","author":"Johnson","year":"2012","journal-title":"Respir Med"},{"key":"10.1378\/chest.12-2396_bib70","author":"National Institutes of Health Clinical Center"},{"issue":"suppl","key":"10.1378\/chest.12-2396_bib71","first-page":"A413","article-title":"Imatinib in pulmonary arterial hypertension, a randomized efficacy study (IMPRES) [abstract]","volume":"38","author":"Hoeper","year":"2011","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1378\/chest.12-2396_bib72","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/kem357","article-title":"Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab","volume":"47","author":"McGonagle","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1378\/chest.12-2396_bib73","author":"National Institutes of Health Clinical Center"},{"issue":"2","key":"10.1378\/chest.12-2396_bib74","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1399-0012.2009.00958.x","article-title":"Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation","volume":"23","author":"Shitrit","year":"2009","journal-title":"Clin Transplant"},{"issue":"12","key":"10.1378\/chest.12-2396_bib75","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1378\/chest.12-2396_bib76","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1378\/chest.12-2396_bib77","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol therapy","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.1378\/chest.12-2396_bib78","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","article-title":"The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension","volume":"186","author":"Mathai","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1378\/chest.12-2396_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1378\/chest.07-0275","article-title":"Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil","volume":"135","author":"Gilbert","year":"2009","journal-title":"Chest"},{"issue":"suppl 5","key":"10.1378\/chest.12-2396_bib80","doi-asserted-by":"crossref","first-page":"v68","DOI":"10.1093\/rheumatology\/ken273","article-title":"The 6-minute walk test in scleroderma\u2014how measuring everything measures nothing","volume":"47","author":"Impens","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1378\/chest.12-2396_bib81","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard.2006.054866","article-title":"Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test","volume":"66","author":"Buch","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1378\/chest.12-2396_bib82","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3899\/jrheum.080447","article-title":"Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma","volume":"36","author":"Garin","year":"2009","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1378\/chest.12-2396_bib83","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3899\/jrheum.081221","article-title":"Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis","volume":"36","author":"Schoindre","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1378\/chest.12-2396_bib84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1183\/09031936.00074309","article-title":"Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension","volume":"35","author":"Mathai","year":"2010","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1378\/chest.12-2396_bib85","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1378\/chest.12-2396_bib86","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00296-007-0510-7","article-title":"N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH","volume":"28","author":"Simeoni","year":"2008","journal-title":"Rheumatol Int"},{"issue":"11","key":"10.1378\/chest.12-2396_bib87","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.amjcard.2011.07.025","article-title":"Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension","volume":"108","author":"Mauritz","year":"2011","journal-title":"Am J Cardiol"},{"issue":"122","key":"10.1378\/chest.12-2396_bib88","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1183\/09059180.00006111","article-title":"Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening","volume":"20","author":"Denton","year":"2011","journal-title":"Eur Respir Rev"},{"issue":"9","key":"10.1378\/chest.12-2396_bib89","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0002-9149(98)00140-4","article-title":"Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension","volume":"81","author":"Yeo","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1378\/chest.12-2396_bib90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.80.2.353","article-title":"Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension","volume":"80","author":"Eysmann","year":"1989","journal-title":"Circulation"},{"issue":"9","key":"10.1378\/chest.12-2396_bib91","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1164\/rccm.200604-547OC","article-title":"Tricuspid annular displacement predicts survival in pulmonary hypertension","volume":"174","author":"Forfia","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1378\/chest.12-2396_bib92","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0735-1097(02)01744-8","article-title":"Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension","volume":"39","author":"Raymond","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1378\/chest.12-2396_bib93","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.3899\/jrheum.110512","article-title":"Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension","volume":"38","author":"Mathai","year":"2011","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1378\/chest.12-2396_bib94","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/eurheartj\/ehl477","article-title":"Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension","volume":"28","author":"van Wolferen","year":"2007","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1378\/chest.12-2396_bib95","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1378\/chest.10-1066","article-title":"Clinically significant change in stroke volume in pulmonary hypertension","volume":"139","author":"van Wolferen","year":"2011","journal-title":"Chest"},{"issue":"1","key":"10.1378\/chest.12-2396_bib96","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.10100725","article-title":"Right and left ventricular myocardial perfusion reserves correlate with right ventricular function and pulmonary hemodynamics in patients with pulmonary arterial hypertension","volume":"258","author":"Vogel-Claussen","year":"2011","journal-title":"Radiology"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369213606819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369213606819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:41:24Z","timestamp":1757918484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369213606819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0012369213606819"],"URL":"https:\/\/doi.org\/10.1378\/chest.12-2396","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Sclerosis-Associated Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.12-2396","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}